To view this email as a web page, click here.
 
MEN’S HEALTH MONDAY
 
Class effect is good news for men with nmCRPC
"While much work is still to be done, we have excellent evidence that there is a beneficial class-like effect for the androgen inhibitors enzalutamide, apalutamide, and darolutamide used within the current definition of men with M0 CPRPC," write Michael Cookson, MD, and Tony Rodriguez, MD.
Read their editorial
 
Novel nonsteroidal AR antagonist shows benefit in treating nmCRPC
Results of a phase III trial show the benefit of darolutamide (Nubeqa) in reducing the risk of metastases or death compared with placebo in men with nonmetastatic castration-resistant prostate cancer.
Learn more
 
SURVEY
 
How concerned are you about the cost of prostate cancer treatment for your patients?
MORE FROM UROLOGY TIMES
 
Researchers develop noninvasive biomarker for aggressive PCa
Urethral lift found safe, efficacious in real-world setting
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.